Evidence map›Paper›PMID 38804544›Full record

ArticleJournal of psychopharmacology (Oxford, England)2024

Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights.

Luke Baxter, Cheneal Puljević, Tim Piatkowski, Jason Ferris, Emma L Davies, Monica J Barratt, Adam Winstock

Abstract read
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luke BaxterSouth London and Maudsley NHS Trust/King's College London, London, UK.
Cheneal PuljevićSchool of Public Health, The University of Queensland, Brisbane, QLD, Australia.
Tim PiatkowskiSchool of Applied Psychology, Griffith Centre for Mental Health, Griffith University, Mount Gravatt, QLD, Australia.ORCID 0000-0002-6177-0266
Jason FerrisCentre for Health Services Research, The University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0001-7474-0173
Emma L DaviesCentre for Psychological Research, Oxford Brookes University, Oxford, UK.
Monica J BarrattSocial Equity Research Centre and Digital Ethnography Research Centre, RMIT University, Melbourne, VIC, Australia.
Adam WinstockGlobal Drug Survey, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe recreational use of LSD, a synthetic psychedelic drug, has surged in recent years, coinciding with a renewed research focus on its potential psychotherapeutic properties.

aimThis study aims to describe the experiences and perceptions of individuals engaging in LSD use for the first time, derived from a large international sample.

methodsThis study utilised 2018 Global Drug Survey data collected from 6 November 2017 to 10 January 2018. Participants who initiated LSD use in the preceding 12 months answered questions on their experiences, social settings, harm-reduction behaviours, and demographics. Descriptive statistics were employed, and characteristics of those seeking emergency medical treatment (EMT) and those not planning further LSD use were compared with other respondents.

resultsAmong 3340 respondents who used LSD in the past year, their first-time experiences generally exceeded expectations, with 97.7% expressing excitement. Adverse and unwanted side effects were rarely reported, and only 17 individuals needed EMT. Feelings of fear were reported by most (64.1%), but only very mildly and not enough to put them off from wanting to use LSD again. DISCUSSION: Although the occurrence of unwanted side effects seems low and the LSD experience is generally pleasurable, vigilance amid the rising illicit use of LSD through harm-reduction education is still important in preventing possible risks.

Indexed as

HallucinogensLysergic Acid DiethylamideAdolescentAdultFearFemaleHarm ReductionHumansMaleMiddle AgedRecreational Drug UseSubstance-Related DisordersSurveys and QuestionnairesYoung AdultHallucinogensLysergic Acid DiethylamideDrugsharm reductionLSDpeerspsychedelic

Identifiers

PMID38804544
PMCPMC11311902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.